[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Generics in Europe - Market Summary, Competitive Analysis and Forecast to 2025

July 2021 | 46 pages | ID: G81E97DDD212EN
MarketLine

US$ 350.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Generics in Europe - Market @Summary, Competitive Analysis and Forecast to 2025

SUMMARY

Generics in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value 2016-20, and forecast to 2025). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

KEY HIGHLIGHTS
  • For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The European generics market had total revenues of $77.9bn in 2020, representing a compound annual growth rate (CAGR) of 7.3% between 2016 and 2020.
  • Market consumption volume increased with a CAGR of 2.2% between 2016 and 2020, to reach a total of 58.1% in 2020.
  • Growth in healthcare spending, which in Germany is significantly above the European average, has helped drive regional growth. The demand for generics is driven by prescription targets and budgets, which leads to generic substitution by pharmacists and physicians.
SCOPE
  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Europe
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Europe
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Europe generics market with five year forecasts
REASONS TO BUY
  • What was the size of the Europe generics market by value in 2020?
  • What will be the size of the Europe generics market in 2025?
  • What factors are affecting the strength of competition in the Europe generics market?
  • How has the market performed over the last five years?
  • What are the main segments that make up Europe's generics market?
1 EXECUTIVE SUMMARY

1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape

2 MARKET OVERVIEW

2.1. Market definition
2.2. Market analysis

3 MARKET DATA

3.1. Market value
3.2. Market volume

4 MARKET SEGMENTATION

4.1. Geography segmentation

5 MARKET OUTLOOK

5.1. Market value forecast
5.2. Market volume forecast

6 FIVE FORCES ANALYSIS

6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry

7 COMPETITIVE LANDSCAPE

7.1. Who are the leading players?
7.2. What are the strengths/weaknesses of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How has the COVID-19 pandemic impacted leading players?

8 COMPANY PROFILES

8.1. Teva Pharmaceutical Industries Limited
8.2. Viatris Inc.
8.3. Pfizer Inc.
8.4. Sanofi SA

9 MACROECONOMIC INDICATORS

9.1. Country data

10 APPENDIX

10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine

LIST OF TABLES

Table 1: Europe generics market value: $ billion, 2016-20
Table 2: Europe generics market volume: %, 2016-20
Table 3: Europe generics market geography segmentation: $ billion, 2020
Table 4: Europe generics market value forecast: $ billion, 2020-25
Table 5: Europe generics market volume forecast: %, 2020-25
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Viatris Inc.: key facts
Table 10: Viatris Inc.: Annual Financial Ratios
Table 11: Viatris Inc.: Key Employees
Table 12: Pfizer Inc.: key facts
Table 13: Pfizer Inc.: Annual Financial Ratios
Table 14: Pfizer Inc.: Key Employees
Table 15: Pfizer Inc.: Key Employees Continued
Table 16: Sanofi SA: key facts
Table 17: Sanofi SA: Annual Financial Ratios
Table 18: Sanofi SA: Key Employees
Table 19: Sanofi SA: Key Employees Continued
Table 20: Europe size of population (million), 2016-20
Table 21: Europe gdp (constant 2005 prices, $ billion), 2016-20
Table 22: Europe gdp (current prices, $ billion), 2016-20
Table 23: Europe inflation, 2016-20
Table 24: Europe consumer price index (absolute), 2016-20
Table 25: Europe exchange rate, 2016-20

LIST OF FIGURES

Figure 1: Europe generics market value: $ billion, 2016-20
Figure 2: Europe generics market volume: %, 2016-20
Figure 3: Europe generics market geography segmentation: % share, by value, 2020
Figure 4: Europe generics market value forecast: $ billion, 2020-25
Figure 5: Europe generics market volume forecast: %, 2020-25
Figure 6: Forces driving competition in the generics market in Europe, 2020
Figure 7: Drivers of buyer power in the generics market in Europe, 2020
Figure 8: Drivers of supplier power in the generics market in Europe, 2020
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Europe, 2020
Figure 10: Factors influencing the threat of substitutes in the generics market in Europe, 2020
Figure 11: Drivers of degree of rivalry in the generics market in Europe, 2020


More Publications